Akebia Therapevics (Akba) gives new employees stock options

Akebia Therapeutics, Inc (NASDAQ:Akba) does One of the 10 best health penny shares to get according to analysts. On June 2, the company, on May 30, 2025, the annual aggregate of the total aggregate of the aggregate of 137,000 shares of 137,000 shares reported that the aggregate of the total aggregate.

Yezry / Shutterstock.com

These options are given to every employee with AKEBIA as an insulating material. The company said that 5635 (c) (c) (c) (c) grants on the list of codes. In addition, the exercise price for the options is $ 3.03 for a share of a share of joint shares in the company’s grant history.

Stock options, in a period of four years, 25% of shares spread on the first anniversary of the grant history. The remaining 75% will come out of the quarterly, if the new employee remained with AKEBIA. Options are the latest after shares of Akebia’s total shares of total shares in eight April 30, 2025 to 88,000.

Akebia Therapeutics, Inc. (Akba: Akba) is a biofarmatia company aimed at developing treatment for kidney diseases. Develops and sells two main products: Auryxia, Phosphorus levels and chronic kidney disease (CKD) and Vafdeo patients, oral drugs for anemia related to CKD.

When we accept the potential as an investment in the Akbay, we believe that the more subsidiary of certain AI shares offers the potential from the bottom and is less risk. If you are looking for an extremely worthless AI Stock to take advantage of the Trump-ERA tariffs and onhoring trends, please see our free report The best short-term EU reserve.

Read the next: Goldman Sachs Energy Shares: Buy 10 shares and The best EU shares to get according to 10 billionaire David Tepper.

Disclosure: No.